NASDAQ:SLS
SELLAS Life Sciences Group Inc. Stock News
$1.46
-0.0100 (-0.680%)
At Close: May 17, 2024
SELLAS Life Sciences to Participate in Upcoming Conferences in October 2021
09:14am, Thursday, 07'th Oct 2021
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel
SELLAS Life Sciences Announces Settlement of Derivative Litigation
04:05pm, Thursday, 23'rd Sep 2021
NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel
SELLAS Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 28th
08:30am, Tuesday, 14'th Sep 2021
NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel
SELLAS Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update
04:22pm, Thursday, 12'th Aug 2021
Reported Promising Updated Clinical Data in Ongoing Clinical Trials of Galinpepimut-S (GPS) in Combination with PD-1 Inhibitors for Malignant Pleural Mesothelioma (MPM) and WT1+ Advanced Ovarian Cance
Sellas Life Sciences Breaks Out Of Pennant Pattern: Technical Levels To Watch
02:49pm, Wednesday, 30'th Jun 2021
SELLAS Life Sciences Group Inc. (NASDAQ: SLS) shares were trading lower Wednesday after the company released updated clinical and initial immunobiological data from a Phase 1/2 clinical trial ofits
Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up
SELLAS Reports Encouraging Updated Clinical Data from Ongoing Mesothelioma Study of Galinpepimut-S (GPS) Combined with Opdivo
08:30am, Thursday, 24'th Jun 2021
Updated Data Show Median Overall Survival of 35.4 Weeks in Patients Treated With Combination Therapy for at Least One Month – Median Overall Survival in Relapse/Refractory Patients with Standard of
SELLAS Life Sciences Announces Inclusion in Russell Microcap® Index
09:05am, Tuesday, 22'nd Jun 2021
NEW YORK, June 22, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel
Sellas Life Sciences Stock May Have Broken Out Of Pennant Pattern: What's Next?
06:11pm, Tuesday, 01'st Jun 2021
SELLAS Life Sciences Group Inc. (NASDAQ:SLS) shares rallied Tuesday as retail traders try to push the stock higher. The stock is likely continuing its momentum after the company secured a U.S. patent
What's Up With Sellas Life Sciences Stock Today?
01:02pm, Friday, 14'th May 2021
Sellas Life Sciences Group Inc (NASDAQ:SLS) shares are trading higher by 8.3% at $8.24 after the company reported first-quarter EPS results up from last year. Sellas Life Sciences reported quarterly
SELLAS Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update
04:25pm, Thursday, 13'th May 2021
Received $1.0 Million Milestone Payment and Recognized $5.7 Million of License Revenue Under Exclusive License Agreement with 3D Medicines for Development and Commercialization of Galinpepimut-S (GPS)
SELLAS Life Sciences to Host Shareholder Update Call on June 3rd
07:30am, Tuesday, 11'th May 2021
NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel c
SELLAS Life Sciences Reports Full Year 2020 Financial Results and Provides Business Update
04:21pm, Tuesday, 23'rd Mar 2021
Entered into Exclusive License Agreement, with $7.5 Million Upfront License Fee and Potential to Receive up to an Additional $194.5 Million, with 3D Medicines for Development and Commercialization of
SELLAS Life Sciences to Participate in the M Vest and Maxim Group Inaugural Emerging Growth Virtual Conference on March 17th
08:30am, Thursday, 11'th Mar 2021
NEW YORK, March 11, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel
Sellas: Late-Stage Biotech Approaches 2023 Approval With Solid Funding
07:29pm, Monday, 22'nd Feb 2021
SELLAS Life Sciences Group, Inc. is a late-stage biopharmaceutical company developing novel cancer immunotherapies. Sellas is currently progressing two therapeutics GalinPepimut-S (Phase 3, Fast Track